PURPOSE: We investigated the efficacy and safety of administering high-dose rituximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients with recurrent B-cell aggressive non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Sixty-seven consecutive patients were treated. Rituximab was administered during stem-cell mobilization (1 day before chemotherapy at 375 mg/m(2) and 7 days after chemotherapy at 1,000 mg/m(2)), together with granulocyte colony-stimulating factor 10 mug/kg and granulocyte-macrophage colony-stimulating factor 250 microg/m(2) administered subcutaneously daily. HD-R of 1,000 mg/m(2) was administered again days 1 and 8 after transplantation. The results of this treatment were retrospectively compared with those of a historical control group receiving the same preparative regimen without rituximab. RESULTS: With a median follow-up time for the study group of 20 months, the overall survival rate at 2-years was 80% (95% CI, 65% to 89%) for the study group and 53% (95% CI, 34% to 69%) for the control group (P = .002). Disease-free survival was 67% (95% CI, 51% to 79%) for the study group and 43% (95% CI, 26% to 60%) for the control group (P = .004). The median time to recovery of absolute neutrophil count to >/= 500 cells/microL was 11 days (range, 8 to 37 days) for the rituximab group and 10 days (range, 8 to 17 days) for the matched control group (P = .001). However, infections were not significantly increased in patients treated with rituximab. CONCLUSION: The results of this study suggest that using HD-R and autologous SCT is a feasible and promising treatment for patients with B-cell aggressive NHL.
PURPOSE: We investigated the efficacy and safety of administering high-dose rituximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients with recurrent B-cell aggressive non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Sixty-seven consecutive patients were treated. Rituximab was administered during stem-cell mobilization (1 day before chemotherapy at 375 mg/m(2) and 7 days after chemotherapy at 1,000 mg/m(2)), together with granulocyte colony-stimulating factor 10 mug/kg and granulocyte-macrophage colony-stimulating factor 250 microg/m(2) administered subcutaneously daily. HD-R of 1,000 mg/m(2) was administered again days 1 and 8 after transplantation. The results of this treatment were retrospectively compared with those of a historical control group receiving the same preparative regimen without rituximab. RESULTS: With a median follow-up time for the study group of 20 months, the overall survival rate at 2-years was 80% (95% CI, 65% to 89%) for the study group and 53% (95% CI, 34% to 69%) for the control group (P = .002). Disease-free survival was 67% (95% CI, 51% to 79%) for the study group and 43% (95% CI, 26% to 60%) for the control group (P = .004). The median time to recovery of absolute neutrophil count to >/= 500 cells/microL was 11 days (range, 8 to 37 days) for the rituximab group and 10 days (range, 8 to 17 days) for the matched control group (P = .001). However, infections were not significantly increased in patients treated with rituximab. CONCLUSION: The results of this study suggest that using HD-R and autologous SCT is a feasible and promising treatment for patients with B-cell aggressive NHL.
Authors: A Varma; R M Saliba; H A Torres; A Afrough; C Hosing; I F Khouri; Y Nieto; N D Shah; S Parmar; Q Bashir; S Ahmed; R B Jones; P Kebriaei; A L Olson; E J Shpall; A M Alousi; M H Qazilbash; R E Champlin; U Popat Journal: Bone Marrow Transplant Date: 2016-03-07 Impact factor: 5.483
Authors: Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass Journal: J Clin Oncol Date: 2012-10-22 Impact factor: 44.544
Authors: Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn Journal: Biol Blood Marrow Transplant Date: 2013-03-22 Impact factor: 5.742
Authors: C Hosing; R M Saliba; G-J Okoroji; U Popat; D Couriel; T Ali; L De Padua Silva; P Kebriaei; A Alousi; M De Lima; M Qazilbash; P Anderlini; S Giralt; R E Champlin; I Khouri Journal: Ann Oncol Date: 2008-02-13 Impact factor: 32.976
Authors: Chitra Hosing; Rima M Saliba; Sheena Ahlawat; Martin Körbling; Partow Kebriaei; Amin Alousi; Marcos De Lima; Julia-Grace Okoroji; John McMannis; Muzaffar Qazilbash; Paolo Anderlini; Sergio Giralt; Richard E Champlin; Issa Khouri; Uday Popat Journal: Am J Hematol Date: 2009-06 Impact factor: 10.047